Ribomic Inc (4591):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ribomic Inc (4591) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9326
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ribomic Inc (Ribomic), a subsidiary of Otsuka Pharmaceutical Co Ltd, is a biopharmaceutical venture company. The company develops molecular targeted pharmaceutical drugs using RNA aptamers. Its technology includes RiboART system a platform technology to treat therapeutic aptamers. Ribomic’s pipeline products include RBM001, RBM002, RBM003, RBM004, RBM005, RBM006, RBM007, RBM008 and RBM101. The company’s products are used to treat pain, sepsis, lung fibrosis and other organ fibrosis, bone diseases, and eye diseases and inflammatory disorders. It has collaboration with other pharmaceutical companies for research and development activities. Ribomic is headquartered in Tokyo, Japan.

Ribomic Inc (4591) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ribomic Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ribomic Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ribomic Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Ribomic Enters into Agreement with Seikagaku 10
Ribomic Enters into Research Agreement with Astellas Pharma 11
Ribomic Enters into Research Agreement with Evec 12
Ribomic Extends Research Agreement with Otsuka Pharma 13
Licensing Agreements 14
Otsuka Pharma to Enter into Licensing Agreement with Ribomic for RBM001 14
Fujimoto Pharma Enters into Licensing Agreement with Ribomic 15
Equity Offering 16
Ribomic Raises USD26 Million in IPO of Shares 16
Ribomic Inc – Key Competitors 18
Ribomic Inc – Key Employees 19
Ribomic Inc – Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Ribomic Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ribomic Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ribomic Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Ribomic Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ribomic Enters into Agreement with Seikagaku 10
Ribomic Enters into Research Agreement with Astellas Pharma 11
Ribomic Enters into Research Agreement with Evec 12
Ribomic Extends Research Agreement with Otsuka Pharma 13
Otsuka Pharma to Enter into Licensing Agreement with Ribomic for RBM001 14
Fujimoto Pharma Enters into Licensing Agreement with Ribomic 15
Ribomic Raises USD26 Million in IPO of Shares 16
Ribomic Inc, Key Competitors 18
Ribomic Inc, Key Employees 19

List of Figures
Ribomic Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ribomic Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Ribomic Inc (4591):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Filinvest Development Corporation (FDC):企業の財務・戦略的SWOT分析
    Filinvest Development Corporation (FDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Agfa-Gevaert N.V. (AGFB):企業の財務・戦略的SWOT分析
    Agfa-Gevaert N.V. (AGFB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Aeroports de Paris SA:戦略・SWOT・企業財務分析
    Aeroports de Paris SA - Strategy, SWOT and Corporate Finance Report Summary Aeroports de Paris SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Jardine Engineering Corporation, Limited:企業の戦略・SWOT・財務情報
    Jardine Engineering Corporation, Limited - Strategy, SWOT and Corporate Finance Report Summary Jardine Engineering Corporation, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • NMDC Ltd:企業のM&A・事業提携・投資動向
    NMDC Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NMDC Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • United Natural Foods Inc:企業の戦略・SWOT・財務情報
    United Natural Foods Inc - Strategy, SWOT and Corporate Finance Report Summary United Natural Foods Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Shanghai Kehua Bio-engineering Co Ltd (002022):企業の財務・戦略的SWOT分析
    Shanghai Kehua Bio-engineering Co Ltd (002022) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Daewoong Pharmaceutical Co Ltd (069620):企業の財務・戦略的SWOT分析
    Daewoong Pharmaceutical Co Ltd (069620) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • AVI Ltd:企業の戦略・SWOT・財務分析
    AVI Ltd - Strategy, SWOT and Corporate Finance Report Summary AVI Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • A.P. Eagers Ltd:企業の戦略・SWOT・財務分析
    A.P. Eagers Ltd - Strategy, SWOT and Corporate Finance Report Summary A.P. Eagers Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • GWA Group Limited (GWA):企業の財務・戦略的SWOT分析
    GWA Group Limited (GWA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • PT. Bank Rakyat Indonesia (Persero) Tbk.:戦略・SWOT・企業財務分析
    PT. Bank Rakyat Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report Summary PT. Bank Rakyat Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Gildan Activewear Inc (GIL):企業の財務・戦略的SWOT分析
    Gildan Activewear Inc (GIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Just Eat Plc:企業の戦略・SWOT・財務分析
    Just Eat Plc - Strategy, SWOT and Corporate Finance Report Summary Just Eat Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Fluor Corporation (FLR):企業の財務・戦略的SWOT分析
    Fluor Corporation (FLR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Orascom Development Egypt Sae:企業の戦略・SWOT・財務分析
    Orascom Development Egypt Sae - Strategy, SWOT and Corporate Finance Report Summary Orascom Development Egypt Sae - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Kellogg Co:企業の戦略・SWOT・財務情報
    Kellogg Co - Strategy, SWOT and Corporate Finance Report Summary Kellogg Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Innovent Biologics Inc (1801):製薬・医療:M&Aディール及び事業提携情報
    Summary Innovent Biologics Inc (Innovent Biologics) is a biopharmaceutical company that discovers, develops and manufactures monoclonal antibodies. The company offers monoclonal antibodies such as IBI301, IBI302 and IBI303, among others. Its products are used for the treatment of non-Hodgkin’s lymph …
  • 220 Laboratories Inc.:企業の戦略・SWOT・財務情報
    220 Laboratories Inc. - Strategy, SWOT and Corporate Finance Report Summary 220 Laboratories Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • NXT Energy Solutions Inc (SFD):企業の財務・戦略的SWOT分析
    Summary NXT Energy Solutions Inc (NXT Energy), formerly Energy Exploration Technologies Inc is an oilfield service company that offers geophysical services to the upstream oil and gas industry. The company provides Stress Field Detection (SFD) a patent pending gravity-based instrument that provides …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆